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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYNew neurons generated by the neural stem cells (NSCs) in the adult hippocampus play an important role in emotional regulation and
respond to the action of antidepressants. Depression is a common and serious side effect of interferon-a (IFN-a), which limits its use
as an antiviral and antitumor drug. However, the mechanism(s) underlying IFN-induced depression are largely unknown. Using a
comprehensive battery of behavioral tests, we found that mice subjected to IFN-a treatment exhibited a depression-like phenotype.
IFN-a directly suppressed NSC proliferation, resulting in the reduced generation of new neurons. Brain-specific mouse knockout of
the IFN-a receptor prevented IFN-a-induced depressive behavioral phenotypes and the inhibition of neurogenesis, suggesting that
IFN-a suppresses hippocampal neurogenesis and induces depression via its receptor in the brain. These findings provide insight for
understanding the neuropathology underlying IFN-a-induced depression and for developing new strategies for the prevention and treat-
ment of IFN-a-induced depressive effects.INTRODUCTION
New neurons are continuously generated in the hippo-
campal dentate gyrus (DG) throughout life in mammals,
including rodents (Altman and Das, 1965; Kaplan and
Hinds, 1977; Kuhn et al., 1996), nonhuman primates
(Gould et al., 1999; Kornack and Rakic, 1999), and humans
(Eriksson et al., 1998; Manganas et al., 2007). In the DG,
neural stem cells (NSCs) residing in the subgranular zone
(SGZ), a thin cell layer between the granule cell layer
(GCL) and the dentate hilus, generate transit-amplifying
intermediate progenitors that give rise to new neurons
(Gage, 2002; Zhao et al., 2008). The newly generated neu-
rons then migrate into the GCL, where they differentiate
into mature granule cells to be integrated into the hippo-
campal circuitry (Mathews et al., 2010; Toni et al., 2007;
van Praag et al., 2002). Evidence suggests that neurogenesis
in this region plays a role in emotional regulation (Eisch
and Petrik, 2012; Samuels and Hen, 2011).
Decreased neurogenesis in the adult DG is implicated in
the pathophysiology of depression, a common psychiatricdisorder. Clinical imaging studies demonstrated reduced
volume and altered metabolism in the hippocampus of
depressed patients (Block et al., 2009; Campbell et al.,
2004; Gilbertson et al., 2002; Huang et al., 2010). Hippo-
campal neurogenesis is downregulated in animal models
of depression induced by exposure to chronic psychosocial
stress (Jacobs et al., 2000; Kempermann and Kronenberg,
2003). Conversely, chronic treatment with antidepressants
enhances hippocampal neurogenesis (Anacker et al., 2011;
Malberg et al., 2000; Pechnick et al., 2011), which is
required for the behavioral effects of these drugs in mice
(Santarelli et al., 2003). However, the relationship between
neurogenesis suppression and depressive symptoms re-
mains elusive (Airan et al., 2007; David et al., 2009; Lucas-
sen et al., 2010). Animal models of depression induced by a
single ligand and its receptor would be useful for investi-
gating thesemechanisms in vivo using genetic approaches.
Interferon-a (IFN-a), a proinflammatory cytokine
with potent antiviral, antiproliferative, and immunoregu-
latory effects, has been widely used to treat chronic viral
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Figure 1. Chronic Treatment with mIFN-a Affects Neurogenesis
in the DG of Adult Mice
(A) Experimental design.
(B–E) Effect of 4-week mIFN-a treatment on SGZ proliferative
activity. The numbers of Ki67+ cells (B and C) and TBR2+ cells (D and
E) in the SGZ were significantly reduced in mIFN-a-treated groups
compared with the PBS-treated group. n = 7 mice per group.
(F and G) Effect of 4-week mIFN-a treatment on NSCs in the DG. The
number of Nestin+ (red) and GFAP+ (green) putative NSCs in the DG
(F, arrows) was significantly reduced by mIFN-a treatment (G) in a
dose-dependent manner. n = 5 mice per group.
(H and I) Effect of mIFN-a treatment on neurogenesis in the DG.
During mIFN-a treatment, BrdU was injected at the beginning of
the fifth week, six times every 8 hr. The number of BrdU+(red) and
DCX+ (green) cells (H, arrows) was significantly reduced in mIFN-
a-treated groups (I). n = 5 mice per group. *p < 0.05, **p < 0.01
versus PBS-treated group; error bars: means ± SEM; scale bars,
100 mm: (B and D), 25 mm: (F and H).
See also Figure S1.
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et al., 2005). However, long-term IFN-a treatment
frequently triggers a variety of neuropsychiatric symptoms74 Stem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authors(Dieperink et al., 2000). Depression is the most common
and serious side effect, affecting approximately 30%–45%
of patients receiving IFN-a treatment, resulting in occa-
sional discontinuation of the therapy (Bonaccorso et al.,
2001; Lieb et al., 2006). Despite its clinical importance,
the mechanism underlying IFN-a-induced depression is
still not well understood.
We previously reported that repeated IFN-a treatment
suppresses cell proliferation in the SGZ of adult rats
(Kaneko et al., 2006). However, little is known about how
peripheral IFN-a affects brain function. Because a small
fraction of peripheral IFN-a gains access to the brain (Greig
et al., 1988; Smith et al., 1985), hippocampal neurogenesis
can be directly affected by the increased IFN-a signaling in
the brain (Wang et al., 2008). However, it is also possible
that IFN-a affects brain function via secondary effectors
such as humoral or cellular components of the peripheral
immune system (Hayley et al., 2013; Orsal et al., 2008).
Here, we analyzed the effects of IFN-a treatment on neu-
rogenesis and depressive behaviors using two types of
interferon-a receptor (IFNAR) knockout (KO) mouse lines:
a systemic KO (IFNAR/; Mu¨ller et al., 1994) and a condi-
tional KO in NSCs and their progenies (IFNARfl/fl:Nes-Cre;
Detje et al., 2009). Our findings suggest that peripherally
administered IFN-a directly suppresses the neurogenic
function of NSCs and increases depression-like behaviors.RESULTS
Chronic mIFN-a Treatment Reduces Cell Proliferation
and Neurogenesis in the DG of Adult Mice
To investigate the effects of chronic mouse IFN-a (mIFN-a)
treatment on cell proliferation in the DG, mice were intra-
peritoneally injected with PBS or mIFN-a daily for 2 or
4 weeks (Figures S1A–S1E available online and Figure 1A).
The numbers of SGZ cells that were positive for the prolif-
eration marker Ki67 (Figures 1B and 1C) and the neuronal
progenitor marker TBR2 (Figures 1D and 1E) were signifi-
cantly reduced by the 4-week, but not the 2-week, mIFN-a
treatment (Figures S1A–S1C). The 4-week mIFN-a
treatment also reduced the number of cells with radial
glia-like morphology expressing the NSC markers Nestin
and GFAP (Figures 1F and 1G). To quantify neurogenesis,
the mice were injected with BrdU six times at 4 weeks of
treatment and fixed at 5 weeks of mIFN-a treatment (Fig-
ure 1A). The number of BrdU+DCX+ new neurons in the
DG was also significantly reduced in mIFN-a-treated mice
compared with PBS-treated controls (Figures 1H and 1I).
To examine the effect of mIFN-a treatment on the sur-
vival and fate of the newly generated cells in the DG, we
labeled the new neurons with bromodeoxyuridine (BrdU)
just before the treatment and quantified the number of
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rons (BrdU+NEUN+ cells) after the 4-week mIFN-a treat-
ment (Figure S1F). There were no significant differences in
the numbers of BrdU+ or BrdU+NEUN+ cells in the DG (Fig-
ures S1G–S1I) or in the percentage of NEUN+ cells in the
BrdU-labeled population (data not shown) between the
treatment groups. We further examined the effects of IFN
treatment on the morphological phenotypes of the new
neurons.Newneuronswere labeled by injecting a retroviral
vector-encoding DsRed (red fluorescent protein) into the
DG 1 day before 4-week mIFN-a treatment. The dendrites
of the DsRed-labeled new neurons were then analyzed.
There were no significant differences in the total length or
number of branching points of dendrites in the DsRed-
labeled new granule cells between the groups (Figures S1J–
S1L), suggesting thatmIFN-adidnot affect theneuronal dif-
ferentiation or the survival of the newly produced cells.
We next examined whether mIFN-a treatment affected
oligodendrocyte progenitor cells, which are widely distrib-
uted and proliferate continuously in the adult brain. There
was no significant difference in the density of OLIG2+
oligodendrocyte progenitor cells between the groups in
any of the brain areas studied (Figure S1M). Taken together,
these data suggest that chronic mIFN-a treatment reduces
the proliferation of neural stem/progenitor cells, reducing
the production of new neurons in the DG.
Treatment of Cultured Neural Stem Cells with mIFN-a
Cultured hippocampal NSCs (Gage et al., 1995) were used
to study the direct effects of mIFN-a on NSCs. Immuno-
cytochemistry revealed that both of the interferon receptor
subunits, IFNAR1 and IFNAR2, were expressed in all the
Nestin+ NSCs (IFNAR1: 100%; IFNAR2: 100%; n = 352 cells;
Figure 2A) and in most of the MAP2+ neurons (IFNAR1:
100%; IFNAR2: 99.17%; n = 121 cells; Figure 2B), GFAP+
astrocytes (IFNAR1: 99.07%; IFNAR2: 99.53%; n = 214 cells;
Figure S2), and RIP+ oligodendrocytes (IFNAR1: 98.85%;
IFNAR2: 100%; n = 87 cells; Figure S2). A 15 min treatment
withmIFN-a dose-dependently increased the phosphoryla-
tion level of STAT1 (a downstream effector of the IFN-a/
IFNAR-signaling pathway; Figure 2C), demonstrating that
hippocampal NSCs were responsive to IFN-a.
To examine mIFN-a’s effects on proliferating hippocam-
palNSCs, we incubatedNSCswith different concentrations
of mIFN-a (10–103 IU/ml). After 24 hr of treatment, there
were no significant differences in cell numbers as deter-
mined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. However, after
further expansion of NSCs at 48 and 72 hr, there was a sig-
nificant dose-dependent reduction in cell numbers of the
IFN-a treatment groups (Figure 2D). To label proliferating
cells, NSCs were incubated with BrdU during the last 4 hr
of culture with PBS or mIFN-a (Figure 2E). mIFN-a dose-dependently reduced the number of BrdU+ proliferating
cells in the Nestin+ NSC populations of 24 hr (data not
shown) and 48 hr (Figure 2F) cultures. The percentage of
PI+ apoptotic cells in the culture was increased by mIFN-a
treatment at higher doses compared with the control (Fig-
ures 2G and 2H), but this effect only accounted for a small
part of the mIFN-a-mediated reduction in NSC expansion
(Figure 2D). These data suggested that mIFN-a directly sup-
presses hippocampal NSC proliferation.
To determine whether mIFN-a affects NSC differentia-
tion, as well as survival of the differentiated cells, the
NSCs were labeled with BrdU and allowed to differentiate
for 72 hr with or without mIFN-a (Figure 2I). mIFN-a had
no effect on the total number of differentiated cells (Fig-
ure 2J) or on the differentiation of BrdU-labeled cells into
MAP2+ neurons, GFAP+ astrocytes, or RIP+ oligodendro-
cytes (Figure 2K). These findings suggest that mIFN-a did
not alter the survival or fates of hippocampal NSCs during
their differentiation. Taken together, our in vivo and
in vitro results indicate that mIFN-a treatment specifically
and directly modulates the proliferation of NSCs.
mIFN-a Treatment Decreases the Proliferative Activity
of Neural Stem/Progenitor Cells in the V-SVZ
We further investigated the effects of mIFN-a on neural
stem/progenitor cells in the ventricular-subventricular
zone (V-SVZ), another region populated with NSCs in the
adult brain. The numbers of cells positive for Ki67 (Figures
3A and 3B) or MASH1 (Figures 3C and 3D), a marker for
transit-amplifying neuronal progenitors, were significantly
reduced in the V-SVZ of mice treated with mIFN-a for
4 weeks. Because the characteristics of the NSCs in the
V-SVZ vary according to region (Kelsch et al., 2007; Merkle
et al., 2007, 2014), we separately quantified and compared
the number of Ki67+ cells in the medial, cortical, dorsal,
lateral, and ventral V-SVZ areas (Merkle et al., 2007) of
each group. The Ki67+ cell population was significantly
decreased in the dorsal and lateral areas in the mIFN-
a-treated groups (Figure S3A).
To examine the effect of mIFN-a on the V-SVZ-derived
NSCs, a neurosphere assay was conducted. The number
of primary neurospheres generated from the V-SVZ of adult
wild-type mice was significantly reduced when the V-SVZ-
derived cells were cultured with 103 IU/ml mIFN-a (Figures
3E and S3B). Moreover, the number of secondary neuro-
spheres formed by dissociated single primary neurospheres
was significantly reduced bymIFN-a (Figure 3F). These data
suggest that mIFN-a inhibited the proliferation and self-
renewal of the V-SVZ NSCs. Notably, sphere formation
from the V-SVZ of IFNAR/ mice was not affected by
mIFN-a treatment (Figure 3E), indicating that the suppres-
sive effects of mIFN-a were mediated by the IFNAR ex-
pressed onNSCs.We also examined the differentiating cellsStem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authors 75
Figure 2. Treatment of Adult Hippo-
campal NSC Cultures with mIFN-a
(A–C) Interferon receptor expression and
STAT1 phosphorylation in cultured adult
hippocampal NSCs. All Nestin+ (A) and
MAP2+ (B) cells (blue) in the culture ex-
pressed both interferon receptor subunits,
IFNAR1 (red) and IFNAR2 (green). A 15 min
incubation with mIFN-a resulted in dose-
dependent increases in STAT1 phosphory-
lation (p-STAT1), as detected by western
blotting, whereas total STAT1 levels were
unchanged (C).
(D–H) Effects of mIFN-a on survival and
proliferation of hippocampal NSCs. The
numbers of live cells quantified by the
MTT assay were significantly reduced in
the mIFN-a-treated groups, compared with
the control groups, at 48 and 72 hr, but not
24 hr (D; n = 3 or 4 wells). The proliferating
NSCs were labeled with BrdU during the last
4 hr of incubation with mIFN-a (E and F).
After 48 hr of incubation with mIFN-a, the
percentage of Nestin+ cells (E, green) that
were BrdU+ (E, red) was reduced in a dose-
dependent manner (F; n = 3 wells). The
percentage of PI+ apoptotic cells (G, red;
Hoechst, blue) was significantly increased
after the 48 hr incubation with mIFN-a (H;
n = 3 wells).
(I–K) Effects of mIFN-a on NSC differentia-
tion. The NSCs labeled with BrdU were
allowed to differentiate for 72 hr with or
without mIFN-a (I). There were no signifi-
cant differences in the number of differen-
tiated cells as quantified by MTT assay (J; n =
3 wells) or the percentage of BrdU-labeled
cells that differentiated into neurons
(MAP2+), astrocytes (GFAP+), or oligoden-
drocytes (RIP+; K; n = 6 wells) among the
groups. *p < 0.05, **p < 0.01 versus PBS-
treated group; error bars: means ± SEM;
scale bars, 25 mm: (A, B, E, G, and I).
See also Figure S2.
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mice. mIFN-a did not affect the survival (Figure 3G) or
neuronal differentiation of these cells (data not shown).
Taken together, these results suggest that mIFN-a directly
suppresses proliferation/self-renewal of the NSCs in the
V-SVZ as well as in the SGZ.76 Stem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The AuthorsChronic mIFN-a Treatment Induces Depressive
Behavioral Phenotypes and Decreases Social
Interactions in Mice
Wenext studied the effects of chronicmIFN-a treatment on
mouse behavior (Figures 4A–4G and S4A–S4L). Mice were
injectedwith PBS ormIFN-a for 4 weeks and then subjected
Figure 3. Effects of mIFN-a Treatment
on NSCs and Neuronal Progenitor Cells
in the Adult V-SVZ
(A–D) Effect of 4-week mIFN-a treatment
on V-SVZ proliferative activity. Following
mIFN-a treatment, the numbers of Ki67+
cells (A and B) and MASH1+ cells (C and D)
in the V-SVZ were significantly reduced in
the mIFN-a-treated group compared with
the PBS-treated group. n = 7 mice per
group.
(E–G) Effects of mIFN-a treatment on
V-SVZ-derived NSC cultures. The number of
primary neurospheres formed by the disso-
ciated V-SVZ cells from wild-type mice
cultured for 7 days was significantly
reduced with 103 IU/ml of mIFN-a. This
effect was not observed with V-SVZ-derived
cells from IFNAR/ mice (E; n = 4 mice per
group). The number of secondary neuro-
spheres formed by the cells dissociated
from single wild-type primary neurospheres
treated with 103 IU/ml of mIFN-a was
significantly reduced compared with un-
treated control cells (F; n = 12 mice per
group). When dissociated cells derived from
primary neurospheres were cultured with
103 IU/ml mIFN-a for 4 days after induction
of differentiation, there was no significant
difference in the number of cells compared
with the control group, as quantified by the
ATP luminescence assay (G; n = 4 cultures). *p < 0.05, **p < 0.01 versus no treatment group; error bars: means ± SEM. The scale bars
represent 100 mm. CNT, control; NS, neurosphere; WT, wild-type.
See also Figure S3.
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and a summary of these tests are shown in the Mouse
Phenotype Database (http://www.mouse-phenotype.org/).
General health, muscular strength (Figures S4A–S4D),
sensorimotor function (Figures 4A, pain sensitivity, and
4B, motor coordination), and locomotor activity (Fig-
ure 4C) were not affected by mIFN-a treatment.
To evaluate anxiety in these mice, we performed
the light/dark transition test (Figures S4E–S4H) and
the elevated plus maze test (Figures S4I–S4L). We also
measured the time spent in the center in the open field
test (Figure 4C, middle). mIFN-a treatment significantly
decreased the distance traveled in the elevated plus maze
test (Figure S4K), but did not affect performance in the
other tests, suggesting that the mIFN-a-treated mice
exhibited a slightly increased sensitivity to stressful envi-
ronmental changes.
Depression-like behaviors in these mice were examined
using the tail suspension test (Steru et al., 1985) and the
Porsolt forced swimming test (Porsolt et al., 1977). In thesetests, depression levels are determined based on immobility
times, which can be elongated by decreased escape-
oriented behaviors. In both tests, the immobility times
were not altered by a 2-week mIFN-a treatment (Figures
S1D and S1E) but were significantly increased by a 5-week
treatment (Figures 4F and 4G), indicating that chronic
mIFN-a treatment induced depressive behavioral pheno-
types, consistent with previous reports (Fahey et al.,
2007; Felger et al., 2007).
To further characterize the IFN-a-induced depression, we
used Crawley’s three-chamber social approach test, which
consists of a sociability test and a social novelty preference
test. This test is useful for monitoring social withdrawal,
one of the typical symptoms of depression, relatively inde-
pendent of their changes in locomotor activity in mice
(Moy et al., 2004). In the sociability test, whereas one
cage was empty, another cage contained a mouse stranger
to the experimental animal (stranger side 1). PBS-treated
mice, placed in the central compartment between these
two cages, spent more time near the cage with the strangerStem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authors 77
Figure 4. Effects of Chronic mIFN-a
Treatment on Mouse Behavioral Profiles
(A–C) Sensorimotor function tests and the
open field test. There were no significant
differences in mouse responses to the hot
plate test (A), the rotarod test (B), or the
open field test (C) between mIFN-a- and
PBS-treated groups. n = 20 to 21 mice per
group.
(D and E) Crawley’s social interaction test.
The time spent near the cage with an un-
familiar (stranger 1) mouse in the socia-
bility test (D, left) or near the cage with a
second unfamiliar (stranger 2) mouse in the
social novelty preference test (E, left) was
significantly longer than the time spent
near an empty cage or the cage containing a
familiar mouse in the PBS-treated group,
but not in the mIFN-a treated group. The
total distance traveled during both tests
was significantly reduced in the mIFN-
a-treated groups compared with the con-
trols (D and E, right). n = 20 to 21 mice per
group; #p < 0.05, ##p < 0.01 stranger side
versus empty (D) or familiar (E) side,
paired-t test; **p < 0.01 versus PBS-treated
group.
(F and G) Tail suspension test (TST) and
forced swimming test (FST). Immobility
times were significantly increased in mIFN-
a-treated groups in both the TST (F) and FST
(G), compared with the PBS-treated groups.
n = 10 mice per group; *p < 0.05, **p < 0.01
versus PBS-treated group. Error bars repre-
sent means ± SEM.
See also Figure S4.
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social novelty preference test, the same animal that had
been a stranger in the sociability test was used as the
familiar one (familiar side), and a new mouse was intro-
duced into the other cage as a stranger (stranger side 2).
PBS-treated mice also spent a significantly longer time
near the cage with the stranger than with the familiar
mouse (Figure 4E, left), because normal mice show more
interest and interaction with novel conspecific mice. In
contrast, mIFN-a-treatedmice did not show this preference
in either test (Figures 4D and 4E, left), suggesting that
mIFN-a treatment impaired the social affiliation/motiva-
tion and social novelty of these mice. In addition, the
decrease in total distance traveled by the mIFN-a-treated
mice compared with the PBS-treated mice (Figures 4D
and 4E, right) may reflect increased anxiety during socially
stressful conditions. We conclude that chronic mIFN-a
treatment of mice induced depressive behaviors and78 Stem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authorsimpaired social interactions without affecting general
health or sensorimotor functions.
mIFN-a Increases Depression-like Behavior and
Reduces Neurogenesis via IFN Receptor Expressed in
the CNS
The direct effects of IFN-a on cultured NSCs (Figures 2
and 3) suggested that receptors for IFN-a expressed in the
brain are involved in suppressing hippocampal neurogene-
sis and inducing depressive behaviors. To test this possibil-
ity, we used two types of knockout mice targeting IFNAR1,
an IFN receptor subunit essential for IFN-a signal transduc-
tion (Mu¨ller et al., 1994): conditional CNS-specific
knockout mice (IFNARfl/fl:Nes-Cre; Detje et al., 2009) and
conventional knockout mice (IFNAR/; Mu¨ller et al.,
1994). These mice were treated with mIFN-a for 5 weeks
and injected with BrdU six times at 8 hr intervals after
4 weeks of treatment using the same protocol as described
Figure 5. Effects of Chronic mIFN-a
Treatment on Hippocampal Neurogenesis
and Behaviors in IFNAR Knockout Mice
(A–F) Effects of 5-week mIFN-a treatment
on neurogenic activity in the DG of
IFNARfl/fl, IFNARfl/fl:Nes-Cre, and IFNAR/
mice. The numbers of Ki67+ proliferating
cells (A and B), TBR2+ neuronal progenitor
cells (C and D), and BrdU+DCX+ newly
generated neurons (E and F) were signifi-
cantly reduced in the mIFN-a-treated group
compared with the PBS-treated group in
IFNARfl/fl mice, but not in IFNARfl/fl:Nes-Cre
or IFNAR/ mice. n = 5 mice per group.
(G and H) Effects of mIFN-a treatment on
the TST and FST. The immobility times in the
TST (G) and FST (H) were significantly
increased in the mIFN-a-treated groups
compared with PBS-treated groups in
IFNARfl/fl mice, but not in IFNARfl/fl:Nes-Cre
or IFNAR/ mice. n = 10–13 mice per
group. *p < 0.05, **p < 0.01 versus PBS-
treated group. The error bars represent
means ± SEM. The scale bars represent
100 mm (A and C) and 25 mm (E).
Stem Cell Reports
Interferon-Induced Depression and Neural Stem Cellabove (Figure 1A). After mIFN-a treatment, the mice were
subjected to the tail suspension test and the Porsolt forced
swimming test and then sacrificed, and the neural progen-
itor cells were analyzed (Figures 5A–5F). Although the
TBR2+ cell population in the PBS-treated groups tended
to be smaller in IFNAR/ and IFNARfl/fl:Nes-Cre mice
compared with IFNARfl/fl mice having normal IFNAR
expression, these differences were not statistically signifi-
cant (Figure 5D). In contrast, chronic mIFN-a treatment
significantly decreased the numbers of Ki67+ (Figures 5A
and 5B), TBR2+ (Figures 5C and 5D), and BrdU+DCX+ (Fig-
ures 5E and 5F) cells in the DG of IFNARfl/fl mice, similar to
the effect in wild-type mice (Figure 1). These effects were
not observed in the IFNAR/ or IFNARfl/fl:Nes-Cre mice(Figures 5A–5F). Similarly, mIFN-a treatment significantly
increased the immobility times in the tail suspension test
and the Porsolt forced swimming test in IFNARfl/fl, but
not IFNARfl/fl:Nes-Cre or IFNAR/ mice (Figures 5G and
5H). Therefore, IFN-a induced hippocampal neurogenesis
suppression and depression-like behavioral changes via
IFNAR expressed in the CNS.DISCUSSION
Depression is one of the most common and serious side
effects of IFN, which can limit its success as an antiviral
or antitumor therapy. In this study, we used a simpleStem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authors 79
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and IFNAR. Rodents treated with mIFN-a were reported
to show depressive behaviors and/or increased anxiety
(Fahey et al., 2007; Makino et al., 1998, 2000b; Yamano
et al., 2000), although several groups failed to reproduce
those behavioral alterations (De La Garza et al., 2005; Loftis
et al., 2006). This discrepancy might result from variations
in experimental paradigms, including the types of IFN-a
used, animal species or lines employed, treatment regi-
mens, and behavioral tests performed. Because the interac-
tion of IFN with IFNAR is highly species specific (Wang
et al., 2008), we chose mouse IFN-a for our animal experi-
ments. Clinical studies showed that patients frequently
develop depressive symptoms after several weeks of IFN-a
administration, but not within the first few weeks (Hauser
et al., 2002; Raison et al., 2005). Similarly, 2-week mIFN-a
treatments did not induce behavioral changes in our
mice (Figure S1). Therefore, we used mice treated with
mIFN-a for over a month to evaluate behavioral changes.
Systemic IFN treatment could affect various brain
functions other than emotional regulation, which might
influence performance in tests assessing depressive-like
behaviors. However, no studies have comprehensively
investigated neurological and/or psychological alterations
of IFN-treated animals. Using a battery of behavioral tests,
we assessed a variety of brain functions. Whereas contin-
uousmIFN-a treatment had no significant effect on general
health or sensorimotor functions within the first 8 weeks,
we noticed a gradual loss of body weight beginning in
the ninth week (data not shown). Therefore, we included
only the data obtained within the first 8 weeks in this
report (Figures 4 and S4) and performed the depression-
like behavioral tests (the tail-suspension test and the
Porsolt forced swimming test) separately from the other
tests, using mice immediately after the 5-week mIFN-a
treatment. As a result, we found that mIFN-a treatment
increased depression-like behaviors and impaired social
interactions (Figures 4 and S4), consistent with the clinical
symptoms of depression and independent of somatic con-
ditions or sensorimotor functions. Taken together, we
conclude that the IFN-a-treated mice are a reliable model
for patients with IFN-induced depression, which is useful
for analyzing the relationship between IFN-a’s effects on
neural stem/progenitor cell function and on the induction
of depressive behaviors.
IFN-a is reported to induce depression via upregulation
of the hypothalamic-pituitary-adrenal (HPA) axis, alter-
ation of monoamine neurotransmission, and induction
of proinflammatory cytokines (Reyes-Va´zquez et al.,
2012; Schaefer et al., 2002). IFN-a can directly interact
with opioid receptors (Jiang et al., 2000), which are also
implicated in the induction of depressive behaviors
(Makino et al., 2000a). Several proinflammatory cytokines,80 Stem Cell Reports j Vol. 3 j 73–84 j July 8, 2014 j ª2014 The Authorsincluding interleukin (IL)-1 and IL-6, have been shown to
modify the neurogenic behavior of NSCs (Gonzalez-Perez
et al., 2012; Kohman and Rhodes, 2013). We previously
found that IFN-a treatment suppresses cell proliferation
in the hippocampal neurogenic region (Kaneko et al.,
2006), which might mediate depression. Here, close exam-
ination revealed that chronic IFN-a treatment reduced the
number of NSCs by nearly 40%, but not that of oligoden-
drocyte progenitors, another population that proliferates
continuously in the adult brain (Figures 1 and S1M). Addi-
tionally, in vitro experiments showed that IFN-a signifi-
cantly inhibited NSC proliferation, but did not affect their
survival or neuronal differentiation, despite the presence of
IFNAR on differentiated neurons, astrocytes, and oligoden-
drocytes (Figures 2, 3, and S2). Taken together, our findings
indicate that NSCs in the adult brain may be a primary
target of IFN-a. Indeed, the neurogenesis inhibition and
depressive-behavior induction by chronic mIFN-a treat-
ment were completely abrogated by CNS-specific and sys-
temic IFNAR knockouts (Figure 5), suggesting that IFNAR
in the brain mediates both of these effects of IFN-a.
Although the IFN-amolecule is large, a small fraction of
systemically administered IFN-a penetrates the brain in
areas where the blood brain barrier is more permeable (Bid-
dle, 2006; Pan et al., 1997). In addition, IFN-a treatment
increased the expression of endogenous IFN-a in the hip-
pocampus (data not shown). Therefore, both exogenously
administered and locally produced IFN-a can be involved
in activating IFNAR signaling in the brain.
Although IFN-a treatment inhibited hippocampal neuro-
genesis and caused depressive behaviors, it is still unclear
whether decreased neurogenesis directly affects mood
and emotional regulation. New neurons have electrophys-
iological features that are distinct from those of mature
granule cells and play a critical role in the plasticity of hip-
pocampal circuitry (Nakashiba et al., 2012; Schmidt-Hieber
et al., 2004), which is considered to be important for adap-
tation to environmental changes and stress coping (Eisch
and Petrik, 2012). However, because ablation of hippo-
campal neurogenesis does not always cause depressive-
like symptoms (Jayatissa et al., 2010), it is controversial
whether new neurons participate in mood or emotional
control (Eisch and Petrik, 2012). Impaired social behavior
coincides with depression-like behaviors in some mouse
lines, such as heat shock factor 1 knockout (Uchida et al.,
2011) and RGS2 mutant (Lifschytz et al., 2012) mice. How-
ever, little is known about the neuronal circuits responsible
for depression-like and/or social behaviors. Further studies
are needed to understand how IFN treatment affects
sociability.
Some proinflammatory cytokines, including IL-1 and
IL-6, induce the secretion of glucocorticoid (Dunn, 2000),
a negative regulator of adult hippocampal neurogenesis.
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the release of corticotropin-releasing hormone in the hypo-
thalamus, followed by activation of the HPA axis (Gis-
slinger et al., 1993). Moreover, hippocampal neurogenesis
negatively regulates the HPA axis, thereby reducing stress
responses (Snyder et al., 2011). Because excessive activa-
tion of the HPA axis is thought to play a role in depression
(Nestler et al., 2002), it is possible that the decreased neuro-
genesis caused by IFN-a (Figures 1 and 5) leads to depres-
sion via HPA axis dysregulation. Thus, although the precise
relationships among depression, neurogenesis, and the
HPA axis remain unclear, their interactions could amplify
the depression-promoting effects of IFN-a.
In conclusion, we demonstrated that chronic peripheral
administration of mIFN-a inhibited neurogenesis and
induced depressive behavioral phenotypes via IFNAR ex-
pressed in the brain. The NSCs were remarkably responsive
to IFN stimulation, exhibiting reduced proliferation and
survival. Althoughmore comprehensive studies are needed
to elucidate the mechanism, these findings improve our
understanding of the neuropathology of IFN-a-induced
effects and may lead to new strategies targeting NSCs
and/or neurogenesis for the prevention and treatment of
IFN-a-induced depression. Furthermore, our simple phar-
macologically induced depression model may be useful
for analyzing the molecular mechanisms of neurogenesis-
dependent mood and emotional regulation.EXPERIMENTAL PROCEDURES
Animals
Male 8-week-old C57BL/6J mice were purchased from SLC.
IFNAR/ (Mu¨ller et al., 1994), IFNARfl/fl (Detje et al., 2009), and
IFNARfl/fl:Nes-Cre mice (Detje et al., 2009; Tronche et al., 1999; at
least 10-fold backcrossed to the C57BL/6J background) were
described previously. All experiments using live animals were per-
formed in accordance with the guidelines and regulations of
Nagoya City University and National Institute for Physiological
Sciences.
mIFN-a Treatment and BrdU Labeling
PBS ormouse IFN-a (mIFN-a; 13 105 or 43 105 IU/kg) dilutedwith
PBS was intraperitoneally injected into mice once a day for 2, 4, or
5 weeks. BrdU was intraperitoneally injected (50 mg/kg) six times
at 8 hr intervals during the first 2 days of the fifth week or just prior
to mIFN-a treatment. The fixed brains were processed to generate
50-mm-thick floating sections as previously described (Kaneko
et al., 2010).
Neural Stem Cell Culture
Adult rat hippocampalNSCswere kindly provided byDr. FredGage
(Salk Institute). Neurosphere cultures were prepared as previously
described (Hitoshi et al., 2002). For details, see Supplemental
Information.Behavioral Testing
A comprehensive battery of behavioral tests was performed as pre-
viously described (Miyakawa et al., 2003; Takao et al., 2010) using
mice that had received a 4-weekmIFN-a (43 105 IU/kg) treatment.
For details, see Supplemental Information.Statistical Analysis
All data were expressed as the mean ± SEM. Differences between
means were determined by two-tailed Student’s t test, one-way
ANOVA, or two-way repeated-measures ANOVA followed by
Tukey-Kramer multiple comparison tests, unless specified other-
wise. A p value of <0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2014.05.015.
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